Outlook Therapeutics Grants Executive Options, FDA-Linked Bonuses

What Happened

• Outlook Therapeutics (OTLK) filed an 8-K (Item 5.02) reporting that on July 21, 2026 its Compensation Committee approved stock option awards and conditional cash bonuses for its named executive officers. CEO Robert C. Jahr received 100,000 options and CFO Lawrence A. Kenyon received 210,078 options under the company’s 2024 Equity Incentive Plan. The options have an exercise price of $1.4304 per share (the Nasdaq closing price on the grant date) and vest/become exercisable on July 21, 2027, subject to continued service.
• The Committee also approved conditional cash bonus opportunities of $420,000 for Mr. Jahr and $200,000 for Mr. Kenyon. Each bonus will be earned and payable only if, on or before July 31, 2026, the FDA approves ONS-5010 (bevacizumab-vikg) and issues a favorable decision on the company’s BLA; bonuses are subject to normal tax withholdings and continued service through payment.

Key Details

• Options granted: CEO Robert C. Jahr — 100,000; CFO Lawrence A. Kenyon — 210,078.
• Exercise price: $1.4304 per share (Nasdaq close on July 21, 2026). Vesting/exercise date: July 21, 2027 (single-date vesting, subject to continued service).
• Conditional cash bonuses: $420,000 (Jahr) and $200,000 (Kenyon), payable only if FDA approval/favorable BLA decision occurs by July 31, 2026.
• Awards given in recognition of executive contributions advancing the ONS-5010 BLA through review and appeal processes and to address non-payment of 2025 annual bonuses.

Why It Matters

• These awards show management compensation is tied directly to regulatory outcomes: the cash bonuses depend on near-term FDA approval of ONS-5010, and the options are retention incentives that vest after one year.
• The exercise price equals market price at grant, so the options have no immediate intrinsic value but could provide future upside if the stock rises. The cash bonuses represent contingent near-term cash obligations if the FDA decision is favorable by July 31, 2026.
• Investors should note the company is signaling that FDA action on ONS-5010 is central to executive compensation and could affect short-term cash flows and management incentives.